AstraZeneca is making a major push into cell therapy with the acquisition of EsoBiotec, a company that has developed a ...

Cambridge-headquartered AstraZeneca is investing $2.5 billion in Beijing to establish its sixth global strategic R & D centre ...

AstraZeneca is making a $1bn investment for the long term, but what lies in store for investors over the next 12 months? Here ...

Discover the top gainers and losers in the S&P 500 Healthcare Index and stay updated on major news like J&J's $55B investment and Pfizer's Haleon stake exit.

AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging field of treatments that can reprogramme immune cells inside patients ...

The companies expect the transaction to close during the second quarter of 2025. AstraZeneca to buy EsoBiotec in $1 billion deal to advance cell therapy ambition EsoBiotec SA has entered into a ...

Learn More. After rising by over 20% since November, the AstraZeneca (LSE:AZN) share price is on a good run. And now management has just signed a $1bn deal to acquire EsoBiotec and further secure ...

AZN to Acquire EsoBiotec; EU Nod for Imfinzi Expanded Use AstraZeneca announced a definitive agreement to acquire Belgium-based, EsoBiotec, a leading vivo cell therapy company for a total ...